WHI-P97

• Description :

  WHI-P97 is a potent and selective JAK-3 inhibitor. WHI-P97 is effective in preventing the development allergic asthma in vivo[1].

• UNSPSC :

  12352005

• Hazard Statement :

  H315, H317, H319, H335

• Target :

  JAK

• Type :

  Reference compound

• Related Pathways :

  Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/WHI-P97.html

• Purity :

  99.70

• Solubility :

  DMSO : 3.33 mg/mL (ultrasonic; warming; heat to 80°C)

• Smiles :

  BrC1=CC(NC2=NC=NC3=CC(OC)=C(OC)C=C32)=CC(Br)=C1O

• Molecular Formula :

  C16H13Br2N3O3

• Molecular Weight :

  455.10

• Precautions :

  H315, H317, H319, H335

• References & Citations :

  [1]R Malaviya, et al. Treatment of allergic asthma by targeting janus kinase 3-dependent leukotriene synthesis in mast cells with 4- (3', 5'-dibromo-4'-hydroxyphenyl) amino-6,7-dimethoxyquinazoline (WHI-P97) . J Pharmacol Exp Ther. 2000 Dec;295 (3) :912-26.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  JAK3

• CAS Number :

  [211555-05-4]